Oppenheimer & Co. Inc. Has $14.41 Million Stake in Zoetis Inc (ZTS)
Oppenheimer & Co. Inc. increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 2.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 143,105 shares of the company’s stock after acquiring an additional 3,334 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $14,406,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc increased its holdings in shares of Zoetis by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after acquiring an additional 293,614 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Zoetis by 9,042.7% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after buying an additional 14,178,765 shares during the last quarter. Polen Capital Management LLC grew its holdings in Zoetis by 1.9% in the 4th quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock valued at $817,212,000 after buying an additional 178,893 shares during the last quarter. FMR LLC grew its holdings in Zoetis by 209.7% in the 4th quarter. FMR LLC now owns 7,245,748 shares of the company’s stock valued at $619,801,000 after buying an additional 4,905,887 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Zoetis by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after buying an additional 785,088 shares during the last quarter. 90.84% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:ZTS traded down $0.87 during trading on Wednesday, hitting $101.10. 1,856,073 shares of the stock were exchanged, compared to its average volume of 2,329,676. Zoetis Inc has a 1-year low of $77.00 and a 1-year high of $103.33. The firm has a market capitalization of $47.46 billion, a PE ratio of 32.30, a PEG ratio of 1.80 and a beta of 0.93. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Investors of record on Thursday, April 18th will be given a dividend of $0.164 per share. The ex-dividend date is Wednesday, April 17th. This represents a $0.66 annualized dividend and a dividend yield of 0.65%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
A number of research firms have issued reports on ZTS. UBS Group began coverage on Zoetis in a report on Wednesday, March 20th. They issued a “neutral” rating on the stock. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and raised their target price for the company from $97.00 to $110.00 in a report on Monday, March 4th. Zacks Investment Research raised Zoetis from a “sell” rating to a “hold” rating in a report on Saturday, February 16th. BMO Capital Markets raised their target price on Zoetis from $93.00 to $101.00 and gave the company a “market perform” rating in a report on Monday, February 25th. Finally, SunTrust Banks began coverage on Zoetis in a report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $101.77.
In related news, insider Roxanne Lagano sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $101.89, for a total transaction of $203,780.00. Following the completion of the transaction, the insider now owns 30,727 shares in the company, valued at approximately $3,130,774.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $86.79, for a total value of $998,085.00. The disclosure for this sale can be found here. Insiders have sold a total of 410,333 shares of company stock valued at $38,674,547 in the last 90 days. 0.29% of the stock is owned by corporate insiders.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Preferred Stock
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.